JP2020536554A - 細胞集団を増大させるための方法および組成物 - Google Patents

細胞集団を増大させるための方法および組成物 Download PDF

Info

Publication number
JP2020536554A
JP2020536554A JP2020520317A JP2020520317A JP2020536554A JP 2020536554 A JP2020536554 A JP 2020536554A JP 2020520317 A JP2020520317 A JP 2020520317A JP 2020520317 A JP2020520317 A JP 2020520317A JP 2020536554 A JP2020536554 A JP 2020536554A
Authority
JP
Japan
Prior art keywords
hsa
mir
population
mrna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020520317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020536554A5 (enExample
Inventor
ジェンルイ リー，
ジェンルイ リー，
ペンシュウ チアン，
ペンシュウ チアン，
リンヘン リー，
リンヘン リー，
チュアン ヘ，
チュアン ヘ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Original Assignee
University of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Chicago filed Critical University of Chicago
Publication of JP2020536554A publication Critical patent/JP2020536554A/ja
Publication of JP2020536554A5 publication Critical patent/JP2020536554A5/ja
Priority to JP2023173609A priority Critical patent/JP2023171952A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
JP2020520317A 2017-10-09 2018-10-09 細胞集団を増大させるための方法および組成物 Pending JP2020536554A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023173609A JP2023171952A (ja) 2017-10-09 2023-10-05 細胞集団を増大させるための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762570076P 2017-10-09 2017-10-09
US62/570,076 2017-10-09
US201862695820P 2018-07-09 2018-07-09
US62/695,820 2018-07-09
PCT/US2018/055092 WO2019074980A1 (en) 2017-10-09 2018-10-09 METHODS AND COMPOSITIONS FOR EXPANSION OF CELL POPULATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023173609A Division JP2023171952A (ja) 2017-10-09 2023-10-05 細胞集団を増大させるための方法および組成物

Publications (2)

Publication Number Publication Date
JP2020536554A true JP2020536554A (ja) 2020-12-17
JP2020536554A5 JP2020536554A5 (enExample) 2021-11-18

Family

ID=66101161

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520317A Pending JP2020536554A (ja) 2017-10-09 2018-10-09 細胞集団を増大させるための方法および組成物
JP2023173609A Pending JP2023171952A (ja) 2017-10-09 2023-10-05 細胞集団を増大させるための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023173609A Pending JP2023171952A (ja) 2017-10-09 2023-10-05 細胞集団を増大させるための方法および組成物

Country Status (6)

Country Link
US (1) US12359200B2 (enExample)
EP (1) EP3694533A4 (enExample)
JP (2) JP2020536554A (enExample)
KR (1) KR102733714B1 (enExample)
CN (2) CN120366217A (enExample)
WO (1) WO2019074980A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046969B2 (en) 2017-05-24 2021-06-29 Epiplanta Biotech Ltd. Transgenic plant and the method for producing the same
CN120366217A (zh) 2017-10-09 2025-07-25 斯托瓦斯医学研究所 用于扩增细胞群的方法和组合物
US20230018989A1 (en) * 2019-07-03 2023-01-19 Children's Medical Center Corporation Inhibiting the rna methyltransferase mettl3 or its interaction with eif3h to suppress oncogene translation and tumorigenesis
CA3180620A1 (en) * 2020-06-09 2021-12-16 Meng Xu Compositions and methods for enhancing immune response
CN116261459A (zh) * 2020-07-09 2023-06-13 中国科学院上海药物研究所 用于抑制ythdf1的组合物和方法
EP4185305A4 (en) * 2020-09-09 2024-08-28 Duke University METHODS OF REPROGRAMMING TARGET CELLS
WO2022086935A1 (en) * 2020-10-19 2022-04-28 The General Hospital Corporation Targeting xist and rna methylation for x reactivation therapy
CN112941102A (zh) * 2021-01-26 2021-06-11 南方医科大学 一种子痫前期小鼠动物模型的构建方法及其应用
CN112941105A (zh) * 2021-02-08 2021-06-11 江西农业大学 一种m6A“阅读器”YTHDF2基因改造方法及其应用
CN112899238B (zh) * 2021-04-01 2023-09-26 中国药科大学 基于RNA-m6A修饰水平的化合物筛选细胞模型及其构建与应用
WO2022241165A2 (en) * 2021-05-12 2022-11-17 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for mutated hotair in the treatment of cancers
CN116024326A (zh) * 2022-09-21 2023-04-28 安徽中医药大学第一附属医院(安徽省中医院) 类风湿关节炎m6A甲基化修饰基因PTEN的应用及其检测方法
CN115463155B (zh) * 2022-11-01 2023-05-23 卡瑞济(北京)生命科技有限公司 间充质干细胞的用途
CN120513295A (zh) * 2023-01-09 2025-08-19 韩国生命工学研究院 Fto基因表达受到抑制的干细胞和由其分化的免疫细胞
WO2024201420A1 (en) * 2023-03-31 2024-10-03 Biorchestra Co., Ltd. Mirna-484 inhibitors and uses thereof
WO2025117708A2 (en) * 2023-11-28 2025-06-05 Baruch S. Blumberg Institute Method and system for use of mutant mrna in liquid biopsies to risk stratify and manage cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160264934A1 (en) * 2015-03-11 2016-09-15 The General Hospital Corporation METHODS FOR MODULATING AND ASSAYING m6A IN STEM CELL POPULATIONS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04503957A (ja) 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
WO1991004753A1 (en) 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
US7018801B2 (en) 2000-02-11 2006-03-28 Board Of Regents, The University Of Texas System Selection of peptides with antibody-like properties
US20070065447A1 (en) 2003-10-29 2007-03-22 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
US8263403B2 (en) * 2007-04-23 2012-09-11 Stowers Institute For Medical Research Methods and compositions for stem cell self-renewal
US9309496B2 (en) 2010-08-23 2016-04-12 The Research Foundation For The State University Of New York Method for expansion of stem cells and the use of such cells
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
ES2672693T3 (es) 2011-04-20 2018-06-15 The Regents Of The University Of California Método para el acondicionamiento y quimioselección combinadas en un único ciclo
CN107207557B (zh) * 2015-01-26 2020-07-10 中国科学院动物研究所 miRNA对m6A修饰水平的调控方法及其应用
CN120366217A (zh) 2017-10-09 2025-07-25 斯托瓦斯医学研究所 用于扩增细胞群的方法和组合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160264934A1 (en) * 2015-03-11 2016-09-15 The General Hospital Corporation METHODS FOR MODULATING AND ASSAYING m6A IN STEM CELL POPULATIONS

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CELL STEM CELL, vol. 13, JPN6022043013, 2013, pages 520 - 533, ISSN: 0004894942 *
GENOMICS PROTEOMICS BIOINFORMATICS, vol. 15, JPN6022043018, May 2017 (2017-05-01), pages 154 - 163, ISSN: 0004894945 *
NATURE, vol. 549, JPN6022043012, September 2017 (2017-09-01), pages 273 - 276, ISSN: 0004894941 *
NUCLEIC ACIDS RESEARCH, vol. 41, no. 21, JPN6022043014, 2013, pages 9753 - 9763, ISSN: 0004894943 *
ウイルス, vol. 第62巻, 第1号, JPN6022043019, 2012, pages 9 - 18, ISSN: 0004894946 *
岩医大歯誌, vol. 39, JPN6022043016, 2014, pages 56 - 65, ISSN: 0004894944 *
生化学, vol. 第87巻, 第4号, JPN6023050156, 2015, pages 413 - 421, ISSN: 0005209374 *

Also Published As

Publication number Publication date
KR20200078536A (ko) 2020-07-01
KR102733714B1 (ko) 2024-11-26
US20200370044A1 (en) 2020-11-26
US12359200B2 (en) 2025-07-15
EP3694533A1 (en) 2020-08-19
CN120366217A (zh) 2025-07-25
JP2023171952A (ja) 2023-12-05
WO2019074980A1 (en) 2019-04-18
CN111511376B (zh) 2025-02-25
EP3694533A4 (en) 2021-07-14
CN111511376A (zh) 2020-08-07

Similar Documents

Publication Publication Date Title
KR102733714B1 (ko) 세포 집단의 증대를 위한 방법 및 조성물
Zhao et al. N-cadherin-expressing bone and marrow stromal progenitor cells maintain reserve hematopoietic stem cells
JP6491661B2 (ja) 幹細胞微粒子及びｍｉＲＮＡ
US10787643B2 (en) Methods, kits, and compositions for stem cell self-renewal
US10526581B2 (en) Modulation of cardiac stem-progenitor cell differentiation, assays and uses thereof
ES3009587T3 (en) Haematopoietic stem/progenitor cells
JP2016507550A (ja) 微粒子の製造方法
US20210161967A1 (en) Extracellular vesicles and uses thereof
EP4159277A1 (en) Method for producing organoid from lung epithelial cells or lung cancer cells
EP3259344A1 (en) Generating arterial endothelial cell populations
Li et al. Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
KR20250026894A (ko) 신장 질환의 치료를 위한 면역특권화 생체활성 신장 세포
US9896659B2 (en) Methods, kits, and compositions for stem cell self-renewal
Kowalski et al. Stromal derived factor‐1 and granulocyte‐colony stimulating factor treatment improves regeneration of Pax7−/− mice skeletal muscles
US12109236B2 (en) Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function
HK40031696B (zh) 用於扩增细胞群的方法和组合物
HK40031696A (en) Methods and compositions for expansion of cell population
AU2008361210A1 (en) An endogenous short hairpin RNA and the use of the same
Espuny Camacho Human pluripotent stem cell-derived cortical neurons for disease modeling and brain repair
Kowalski The role of Sdf-1 in the migration and differentiation of stem cells during skeletal muscle regeneration.
Abramov et al. Cells interactions and cells modifications via exosomes
Ivanova et al. Secretion mechanisms of Wnt proteins
Muttini et al. Characterization, GFP gene nucleofection and allotransplantation in injured tendons of ovine amniotic fluid-derived stem cells
Copley Regulation of developmental changes in hematopoietic stem cell self-renewal
Durand Regulation of hematopoietic stem cell migration and function

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231005

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231013

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231208